Wikipedia -WSS

Wikipedia

author：fashion 2025-09-30 23:05:58 - browse：86248

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： How Long Island became the ‘eugenics capital of the world’

explore

hotspot

WSS

Complete sequence of Y chromosome published for first time

Medicare reduced heart disease by changing how it pays doctors

Why more medical students aren't specializing in primary care

2023 STAT Wunderkinds: get to know the winners

Medicare reduced heart disease by changing how it pays doctors

Neuroscience startup Neumora files for IPO

explore

Wikipedia

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

AstraZeneca bets AAV gene therapy will still deliver the goods

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

First Opinion Podcast: Long Covid needs a new approach

At least 13 dead in Texas as scorching temps continue

FDA struggles to regulate food additives, sometimes for decades

Bright Health sells Medicare Advantage business to Molina

How Long Island became the ‘eugenics capital of the world’

Medicare details structure of new drug price negotiation program

What do new weight loss drugs mean for bariatric surgery?

focus

Beam Therapeutics to lay off 20% of its staff, re

Researchers explore possible ties between long Covid, menopause

UnitedHealth’s board chair also owns a personal investment firm

How to make AI work for medicine

FDA panel gives mixed vote on blood pressure devices

FDA gives detailed accounting of AI

explore

hotspot

hotspot

entertainment